Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered into a strategic partnership to deliver drug substance manufacturing services.

But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.

AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...